Impact Biomedical 10% owner DSS sells 906 shares

DSS, Inc. is identified as a ten percent owner, and no Rule 10b5-1 plan is reported for these sales.

Rhea-AI Filing Summary

DSS, Inc., identified as a ten percent owner of Impact Biomedical Inc. (IBO), reported direct sales totaling 906 common shares: 723 shares on September 22, 2026, at $0.5500 per share; 27 shares on September 23 at $6.9500; and 156 shares on September 24 at $7.0587. No Rule 10b5-1 plan is reported.

Insider Trade Summary

Net Seller: 906 shares

Net Sell 3 txns

Insider DSS, INC.

Role 10% Owner

Sold 906 shs ($2K)

Type	Security	Shares	Price	Value
Sale	Common Stock	156	$7.0587	$1K
Sale	Common Stock	27	$6.95	$187.65
Sale	Common Stock	723	$0.55	$397.65

Holdings After Transaction: Common Stock — 589,518 shares (Direct)

Key Figures

Common shares sold: 723 shares Sale price per share: $0.5500 per share Common shares sold: 27 shares +3 more

6 metrics

Common shares sold 723 shares September 22, 2026; direct sale

Sale price per share $0.5500 per share September 22, 2026

Common shares sold 27 shares September 23, 2026; direct sale

Sale price per share $6.9500 per share September 23, 2026

Common shares sold 156 shares September 24, 2026; direct sale

Sale price per share $7.0587 per share September 24, 2026

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many IBO shares did DSS, Inc. sell and at what prices?

DSS, Inc. reported direct sales totaling 906 IBO common shares: 723 shares at $0.5500 per share on September 22, 2026; 27 at $6.9500 on September 23; and 156 at $7.0587 on September 24.

Did DSS, Inc.'s IBO sales use a Rule 10b5-1 plan?

No Rule 10b5-1 plan is reported for the sales.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/24/2026 - 07:38 PM Accepted by SEC EDGAR 09/24/2026 - 07:37 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DSS, INC.

(Last) (First) (Middle)

275 WIREGRASS PKWY

(Street)

HENRIETTA NEW YORK 14586

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IMPACT BIOMEDICAL INC. [ IBO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/22/2026		S		723	D	$0.55	589,701	D
Common Stock	09/23/2026		S		27	D	$6.95	589,674	D
Common Stock	09/24/2026		S		156	D	$7.0587	589,518	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

This entity is a wholly-owned subsidiary of DSS, Inc.

	/s/ Jason Grady	09/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)